Closing the gap between clinic and cage: Sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 36, Issue 10, 2012, Pages 2305-2324

  Pienaar, Ilse S ^a,b   Lu, Bingwei ^b,c   Schallert, Timothy ^b,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Animal models; Behaviour; Motor function; Non motor function; Parkinson's disease; Testing

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPA RECEPTOR; AMPHETAMINE; BAICALEIN; BL 1023; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; METHAMPHETAMINE; NEURITE PROMOTING FACTOR; NEUROPROTECTIVE AGENT; NEUROTOXIN; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANXIETY DISORDER; ASSOCIATION; BODY EQUILIBRIUM; COGNITION; COGNITIVE DEFECT; DISTRESS SYNDROME; DOWN REGULATION; DYSKINESIA; ELECTROENCEPHALOGRAM; EXECUTIVE FUNCTION; FUNCTIONAL ASSESSMENT; GAIT; HUMAN; MAZE TEST; MOTOR CONTROL; MOTOR COORDINATION; NEGLECT; NERVE CELL LESION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; ROTAROD TEST; SENSORIMOTOR FUNCTION; SENSORIMOTOR INTEGRATION; TASK PERFORMANCE; UPREGULATION;

EID: 84868261084     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.07.009     Document Type: Review

References (274)

1. Adams, J.D., Kalivas, P.W., Miller, C.A., 1989. The acute histopathology of MPTP in the mouse CNS. Brain Research Bulletin 23, 1-17.
2. Alam, M., Schmidt, W.J., 2002. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behavioural Brain Research 136, 317-324.
3. Alam, M., Mayerhofer, A., Schmidt, W.J., 2004. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behavioural Brain Research 151, 117-124.
4. Anichtchik, O., Diekmann, H., Fleming, A., Roach, A., Goldsmith, P., Rubisztein, D.C., 2008. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. Journal of Neuroscience 28, 8199-8207.
5. Annett, L.E., Martel, F.L., Rogers, D.C., Ridley, R.M., Baker, H.F., Dunnett, S.B., 1994. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Experimental Neurology 125, 228-246.
6. Annett, L.E., Torres, E.M., Clarke, D.J., Ishide, Y., Barker, R.A., Ridley, R.M., Baker, H.F., Dunnett, S.B., 1997. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplantation 6, 557-569.
7. Anstrom, K.K., Schallert, T., Woodlee, M.T., Shattuck, A., Roberts, D.C.S., 2007. Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease. Behavioural Brain Research 179, 183-191.
8. Antelman, S.M., Caqqiula, A.R., 1977. Norepinephrine-dopamine interactions and behavior. Science 195, 646-653.
9. Ariano, M.A., Grissell, A.E., Littlejohn, F.C., Buchanan, T.M., Elsworth, J.D., Collier, T.J., Steece-Collier, K., 2005. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems. Journal of Neuroscience Research 82, 387-396.
10. Ba, M., Kong, M., Yang, H., Ma, G., Lu, G., Chen, S., Liu, Z., 2006. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats. Neurochemical Research 31, 1337-1347.
11. Barbosa, E.R., Limongi, J.C.P., Cummings, J.L., 1997. Parkinson's disease. In: Miguel, E.C., Rauch, S.L., Leckman, J.F. (Eds.), The Psychiatric Clinics of North America Volume 20 Number 4: Neuropsychiatry of the Basal Ganglia. Saunders, Philadelphia, pp. 769-790.
12. Bata-García, J.L., Villanueva-Toledo, J., Gutiérrez-Ospina, G., Alvarez-Cervera, F.J., Heredia-López, F.J., Góngora-Alfaro, J.L., 2007. Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl. Pharmacology, Biochemistry, and Behavior 86, 68-78.
13. Battig, K., Rosvold, H.E., Mishkin, M., 1960. Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys. Journal of Comparative Psychology 53, 400-404.
14. Beal, M.F., 2001. Experimental models of Parkinson's disease. Nature Reviews. Neuroscience 2, 325-334.
15. Berger, K., Przedborski, S., Cadet, J.L., 1991. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal injection in rats. Brain Research Bulletin 26, 301-307.
16. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 20, 415-455.
17. Bertrand, E., Lechowicz, W., Szpak, G.M., Dymecki, J., 1997. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathologica 35, 80-86.
18. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T., 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 3, 1301-1306.
19. Bezard, E., Gross, C.E., Fournier, M.C., Dovero, S., Bloch, B., Jaber, M., 1999. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Experimental Neurology 155, 268-273.
20. Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., et al., 2001. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinelesioned macaque model of Parkinson's Disease. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21, 6853-6861.
21. Bindoff, L.A., Birch-Machin, M., Cartlidge, N.E., Parker Jr., W.D., Turnbull, D.M., 1989. Mitochondrial function in Parkinson's disease. Lancet 2, 49.
22. Blume, S.R., Cass, D.K., Tseng, K.Y., 2009. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Experimental Neurology 219, 208-211.
23. Bonanni, L., Thomas, A., Anzellotti, F., Monaco, D., Ciccocioppo, F., Varanese, S., Bifolchetti, S., D'Amico, M.C., et al., 2010. Protracted benefit from paradoxical kinesia in typical and atypical parkinsonism's. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 31, 751-756.
24. Borland, M.K., Trimmer, P.A., Rubinstein, J.D., Keeney, P.M., Mohanakumar, K.P., Liu, L., Bennett, J.P., 2008. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Molecular Neurodegeneration 3, 21.
25. Borlongan, C.V., Randall, T.S., Cahil, D.W., Sanberg, P.R., 1995. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain Research 676, 231-234.
26. Bosboom, J.L., Stoffers, D., Wolters, Ech., 2004. Cognitive dysfunction and dementia in Parkinson's disease. Journal of Neural Transmission 111, 1303-1315.
27. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N., Braak, E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 24, 197-211.
28. Broida, J., Svare, B., 1982. Strain-typical patterns of pregnancy-induced nest-building in mice: maternal and experiential influences. Physiology & Behavior 29, 53-57.
29. Brück, A., Portin, R., Lindell, A., Laihinen, A., Bergman, J., Haaparanta, M., Solin, O., Rinne, J.O., 2001. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neuroscience Letters 311, 81-84.
30. Brundin, P., Isacson, O., Gage, F.H., Björklund, A., 1986a. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target or non-target cells. Brain Research 389, 77-84.
31. Brundin, P., Isacson, O., Gage, F.H., Prochiantz, A., Björklund, A., 1986b. The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Research 366, 346-349.
32. Brundin, P., Strecker, R.E., Gage, F.H., Lindvall, O., Björklund, A., 1988. Intracerebral transplantation of dopamine neurons: understanding the functional role of the mesolimbocortical dopamine system and developing a therapy for Parkinson's disease. Annals of the New York Academy of Sciences 537, 148-160.
33. Burack, M.A., Hartlein, J., Flores, H.P., Taylor-Reinwald, L., Perlmutter, J.S., Cairns, N.J., 2010. In vivo amyloid imaging in autopsy-confirmed Parkinsondisease with dementia. Neurology 74, 77-84.
34. Cadet, J.L., Last, R., Kostic, V., Przedborski, S., Jackson, V., 1991. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudateputamen. Brain Research Bulletin 26, 707-713.
35. Cadet, J.L., Zhu, S.M., 1992. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Research 595, 316-326.
36. Calon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P.J., Bedard, P.J., Di Paolo, T., 2002. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Progress in Neuro-psychopharmacology & Biological Psychiatry 26, 127-138.
37. Calon, F., Morissette, M., Rajput, A.H., Hornykiewicz, O., Bedard, P.J., Di Paolo, T., 2003. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Movement Disorders: Official Journal of the Movement Disorder Society 18, 241-253.
38. Cenci, M.A., Whishaw, I.Q., Schallert, T., 2002. Animal models of neurological deficits: how relevant is the rat? Nature Reviews. Neuroscience 3, 574-579.
39. Chan-Palay, V., Asan, E., 1989. Alterations in catecholamine neurons of the locus coerulesu in senile demetia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. The Journal of Comparative Neurology 287, 373-392.
40. Chang, J.-W., Wachtel, S.R., Young, D., Kang, U.-J., 1999. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88, 617-628.
41. Chen, H., Zhang, S.M., Swartzchild, M.A., Hernan, M.A., Ascherio, A., 2005. Physical activity and the risk of Parkinson disease. Neurology 64, 664-669.
42. Chen, S.F., Hsu, C.W., Huang, W.H., Wang, J.Y., 2008. Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after Exp. traumatic brain injury. British Journal of Pharmacology 155, 1279-1296.
43. Chiang, Y.C., Chen, P.C., Chen, J.C., 2003. D(3) dopamine receptors are downregulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Research 972, 159-167.
44. Choi-Lundberg, D.L., Lin, Q., Schallert, T., Crippens, D., Davidson, B.L., Chang, Y.N., Qian, J., Bardwaj, L., et al., 1998. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor GDNF in the striatum and substantia nigra of the aged Parkinsonian rat. Experimental Neurology 154, 261-275.
45. Cohen, A.D., Tillerson, J.L., Smith, A.D., Schallert, T., Zigmond, M.J., 2003. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. Journal of Neurochemistry 85, 299-305.
46. Cordeiro, K.K., Jiang, W., Papazoglou, A., Tenório, S.B., Döbrössy, M., Nikkhah, G., 2010. Graft-mediated functional recovery on a skilled forelimb use paradigm in a rodent model of Parkinson's disease is dependent on reward contingency. Behavioural Brain Research 212, 187-195.
47. Crizzle, A.M., Newhuse, I.J., 2006. Is physical exercise beneficial for persons with Parkinson's disease? Clinical Journal of Sport Medicine: Official Journal of the Canadian Academy of Sport Medicine 16, 422-425.
48. Cui, M., Aras, R., Christian, W.V., Rappold, P.M., Hatwar, M., Panza, J., et al., 2009. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proceedings of the National Academy of Sciences of the United States of America 106, 8043-8048.
49. Cui, L., Zhang, X., Yang, R., Liu, L., Wang, L., Li, M., et al., 2010. Baicalein is neuroprotective in rat MCAO model: role of 12/15- lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2. Pharmacology, Biochemistry, and Behavior 96, 469-475.
50. Cummings, J.L., 1988. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. Journal of Geriatric Psychiatry and Neurology 1, 24-36.
51. Da Cunha, C., Wietzikoski, E.C., Ferro, M.M., Martinez, G.R., Vital, M.B.F., Hipolide, D., et al., 2008. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission. Behavioural Brain Research 189, 364-372.
52. Dagher, A., Owen, A.M., Boecker, H., Brooks, D.J., 2001. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 124, 1020-1032.
53. Dauer, W., Przedborski, S., 2003. Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
54. Deguil, J., Jailloux, D., Page, G., Fauconneau, B., Houeto, J.L., Philippe, M., Muller, J.M., Pain, S., 2007. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+ -induced alteration of translational control in Neuro-2a neuroblastoma cells. Journal of Neuroscience Research 85, 2017-2025.
55. Deguil, J., Chavant, F., Lafay-Chebassier, C., Pérault-Pochat, M.C., Fauconneau, B., Pain, S., 2010. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotoxicity Research 17, 1420155.
56. De Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartiques, J.F., Baldereschi, M., Fratiglioni, L., Lobo, A., et al., 2000. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurological diseases in the elderly research group. Neurology 54, S21-S23.
57. De la Fuente-Fernandez, R., Phillips, A.G., Zamburlini, M., Sossi, V., Calne, D.B., Ruth, T.J., Stoessl, A.J., 2002. Dopamine release in human ventral striatum and expectation of reward. Behavioural Brain Research 136, 359-363.
58. Deumens, R., Blokland, A., Prickaerts, J., 2002. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Experimental Neurology 175, 303-317.
59. Dobbing, J., Sands, J., 1979. Comparative aspects of the brain growth spurt. Early Human Development 1, 79-83.
60. Dowd, E., Monville, C., Torres, E.M., Dunnett, S.B., 2005. The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Research Bulletin 68, 24-30.
61. Ekstrand, M.I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., et al., 2007. Progressive parkinsonism in mice with respiratorychain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America 104, 1325-1330.
62. Fahn, S., Sulzer, D., 2004. Neurodegeneration and neuroprotection in Parkinson disease. Neurotherapeutics 1, 139-154.
63. Fama, R., Sullivan, E.V., Shear, P.K., Stein, M., Yesavage, J.A., Tinklenberg, J.R., Pfefferbaum, A., 2000. Extent, pattern, and correlates of remote memory impairment in Alzheimer's disease and Parkinson's disease. Neuropsychology 14, 265-276.
64. Faradji, J., Metz, G.A., 2006. Sequential bilateral striatal lesions have additive effects on single skilled limb use in rats. Behavioural Brain Research 177, 195-204.
65. Faull, R.L., Laverty, R., 1969. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Experimental Neurology 23, 332-340.
66. Fearnley, J.M., Lees, A.J., 1991. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
67. Fearnley, J.M., Lees, A.J., 1994. Ageing is not involved in the pathophysiology of Parkinson's disease. Brain 114, 2283-2301.
68. Ferro, M.M., Bellissimo, M.I., Anselmo-Franci, J.A., Angellucci, M.E., Canteras, N.S., Da Cunha, C., 2005. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. Journal of Neuroscience Methods 148, 78-87.
69. Ferrante, R.J., Schluz, J.B., Kowall, N.W., Beal, M.F., 1997. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not the substantia nigra. Brain Research 753, 157-162.
70. Fitzsimmons, D.F., Moloney, T.C., Dowd, E., 2006. Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism. Behavioural Brain Research 169, 352-355.
71. Fleming, S.M., Salcedo, J., Fernagut, P.O., Rockenstein, E., Masliah, E., Levine, M.S., Chesselet, M.-F., 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 24, 9434-9440.
72. Fleming, S.M., Delville, Y., Schallert, T., 2005. An intermittent, controlled rate slow progressive degeneration model of Parkinson's disease: anti-parkinson effects of Sinemet and protective effects of methylphenidate. Behavioural Brain Research 156, 201-213.
73. Flowers, K.A., Pearce, I., Pearce, J.M.S., 1984. Recognition memory in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 47, 1174-1181.
74. Fornai, F., Schlüter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferruci, M., et al., 2005. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 102, 3413-3418.
75. Forno, L.S., DeLanney, L.E., Irwin, I., Langston, J.W., 1993. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Advances in Neurology 60, 600-608.
76. Francardo, V., Recchia, A., Popovic, N., Andersson, D., Nissbrandt, H., Censi, M.A., 2011. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiology of Disease 42, 327-340.
77. Fredriksson, A., Archer, T., 1994. MPTP-induced behavioural and biochemical deficits: a parametric analysis. Journal of Neural Transmission 7, 123-132.
78. Freedman, M., Oscar-Berman, M., 1986. Selective delayed response deficits in Parkinson's and Alzheimer's disease. Archives of Neurology 43, 886-890.
79. Fukui, M., Rodriquiz, R.M., Zhou, J., Jiang, S.X., Phillips, L.E., Caron, M.G., Wetsel, W.C., 2007. Vmat2 heterozygous mutant mice display a depressive-like phenotype. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 27, 10520-10529.
80. Gage, F.H., 1993. Parkinson's disease. Fetal implants put to the test. Nature 361, 405-406.
81. German, D.C., Dubach, M., Askari, S., Speciale, S.G., Bowden, D.M., 1988. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
82. Gesi, M., Soldani, P., Giorgi, F.S., Santinami, A., Bonaccorsi, I., Fornai, F., 2000. The role of the locus coeruleus in the development of Parkinson's disease. Neuroscience and Biobehavioral Reviews 24, 655-668.
83. Gibb, W.R., Lees, A.J., 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's Disease. Journal of Neurology, Neurosurgery, and Psychiatry 51, 745-752.
84. Gibb, W.R.G., Lees, A.J., 1994. Pathological clues to the cause of Parkinson's disease. In: Marsden, C.D., Fahn, S. (Eds.), Movement Disorders. Butterworth-Heinemann, Oxford, pp. 147-166.
85. Glajch, K.E., Fleming, S.M., Surmeier, D.J., Osten, P., 2012. Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease. Behavioural Brain Research 230, 309-316.
86. Goerendt, I.K., Lawrence, A.D., Brooks, D.J., 2004. Reward processing in health and Parkinson's disease: neural organization and reorganization. Cerebral Cortex 14, 73-80.
87. Grealish, S., Mattsson, B., Draxler, P., Björklund, A., 2010. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. The European Journal of Neuroscience 31, 2266-2278.
88. Halliday, G., Herrero, M.T., Murphy, K., McCann, H., Ros-Bernal, F., Barcia, C., et al., 2009. No Lewy pathology in monkeys with over 1- years of severe MPTP Parkinsonism. Movement Disorders: Official Journal of the Movement Disorder Society 24, 1519-1523.
89. Hefti, F., Melamed, E., Wurtman, R.J., 1980. Partial lesions of the DAergic nigrostriatal system in the rat brain: biochemical characterization. Brain Research 195, 123-137.
90. Heikkila, R.E., Nicklas, W.J., Vyas, I., Duvoisin, R.C., 1985. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neuroscience Letters 62, 389-394.
91. Herrera-Marschitz, M., Arbuthnott, G., Ungerstedt, U., 2010. Therotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond. Progress in Neurobiology 90, 176-189.
92. Heuer, A., Smith, G.A., Lelos, M.J., Lane, E.L., Dunnett, S.B., 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural Brain Research 228, 30-43.
93. Ho, Y.J., Ho, S.C., Pawlak, C.R., Yeh, K.Y., 2011. Effects of D-cycloserine on MPTPinduced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behavioural Brain Research 219, 280-290.
94. Hoehn, M.M., Yahr, M.D., 1967. Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
95. Hofman, A., Collette, H.J., Bartelds, A.I., 1989. Incidence and risk factors of Parkinson's disease in the Netherlands. Neuroepidemiology 8, 296-299.
96. Höglinger, G.U., Feger, J., Prigent, A., Michel, P.P., Parain, K., Champy, P., Ruberg, M., Oertel, W.H., et al., 2003. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. Journal of Neurochemistry 84, 491-502.
97. Höglinger, G.U., Lannuzel, A., Khondiker, M.E., Michel, P.P., Duyckaerts, C., Féger, J., Champy, P., Prigent, A., et al., 2005. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. Journal of Neurochemistry 95, 930-939.
98. Höglinger, G.U., Oertel, W.H., Hirsch, E.C., 2006. The rotenone model of parkinsonism-the five year inspection. Journal of Neural Transmission. Supplementum 70, 269-272.
99. Hornykiewicz, O., Kish, S.J., 1987. Biochemical pathophysiology of Parkinson's disease. Advances in Neurology 45, 19-34.
100. Hutter-Saunders, J.A., Kosloski, L.M., McMillan, J.M., Yotam, N., Rinat, T., Mosley, R.L., Gendelman, H.E., 2011. BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience 180, 293-304.
101. Hutter-Saunders, J.A., Gendelman, H.E., Mosley, R.L., 2012. Murine motor and behavior functional evaluations for acute 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine MPTP intoxication. Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology 7, 279-288.
102. Im, H.I., Joo, W.S., Nam, E., Lee, E.S., Hwang, Y.J., Kim, Y.S., 2005. Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. Journal of Pharmacological Sciences 98, 185-189.
103. Iwaniuk, A.N., Whishaw, I.Q., 2000. On the origin of skilled forelimb movements. Trends in Neurosciences 23, 372-376.
104. Jarvis, M.F., Wagner, G.C., 1985. Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neuropharmacology 24, 581-583.
105. Jenner, P., 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 13, 24-34.
106. Jeon, B.S., Jackson-Lewis, V., Burke, R.E., 1995. 6-Hydroxydopamine lesion of the rat substantia nigra: Tme course and morphology of cell death. Neurodegeneration 4, 131-137.
107. Jobges, M., Heuschkel, G., Pretzel, C., Illhart, C., Renner, C., Hummelsheim, H., 2004. Repetitive training of compensatory steps: a therapeutic approach for postural stability in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 75, 1682-1687.
108. Jones, T.A., Schallert, T., 1992. Overgrowth and pruning of dendrites in adult rats recovering from neoicortical damage. Brain Research 581, 156-160.
109. Jones, T.A., Schallert, T., 1994. Use-dependent growth of pyramidal neurons after neocortical damage. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14, 2140-2152.
110. Kahlig, K.M., Binda, F., Khosbouei, H., 2005. Amphetamine induced dopamine efflux through a dopamine transporter channel. Proceedings of the National Academy of Sciences of the United States of America 102, 3495-3500.
111. Kaminsky, T.A., Dudgeon, B.J., Billingsley, F.F., Mitchell, P.H., Weghorst, S.J., 2007. Virtual cues and functional mobility of people with Parkinson's disease: a singlesubject pilot study. Journal of Rehabilitation Research and Development 44, 437-448.
112. Karachi, C., Grabli, D., Bernard, F.A., Tandé, D., Wattiez, N., Belaid, H., Bardinet, E., Prigent, A., et al., 2010. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. The Journal of Clinical Investigation 120, 2745-2754.
113. Keefe, K.A., Salamone, J.D., Zigmond, M.J., Stricker, E.M., 1989. Paradoxical kinesia in parkinsonism is not caused by dopamine release. Studies in an animal model. Archives of Neurology 46, 1070-1075.
114. Keefe, K.A., Stricker, E.M., Zigmond, M.J., Abercrombie, E.D., 1990. Environmental stress increases extracellular dopamine in striatum of 6-hydroxydopaminetreated rats: in vivo microdialysis studies. Brain Research 527, 350-353.
115. Kirik, D., Rosenblad, C., Bjorklund, A., 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Experimental Neurology 152, 259-277.
116. Klein, A., Metz, G.A., Papazoglou, A., Nikkhah, G., 2007. Differential effects on forelimb grasping behavior induced by fetal dopaminergic grafts in hemiparkinsonian rats. Neurobiology of Disease 27, 24-35.
117. Klein, C., Westenberger, A., 2012. Genetics of Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2, a008888.
118. Klein, A., Sacrey, L.-A., Whishaw, I.Q., Dunnett, S.B., 2012. The use of skilled reaching as a translational model for investigating brain damage and disease. Neuroscience and Biobehavioral Reviews 36, 1030-1042.
119. Kobylecki, C., Cenci, M.A., Crossman, A.R., Ravenscroft, P., 2010. Calcium-permeable AMPA receptors are involved in the induction and expression of L-DOPAinduced dyskinesia in Parkinson's disease. Journal of Neurochemistry 114, 499-511.
120. Konitsiotis, S., Blanchet, P.J., Verhagen, L., Lamers, E., Chase, T.N., 2000. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589-1595.
121. Kowall, N.W., Hantraye, P., Brouillet, E., Beal, M.F., McKee, A.C., Ferrante, R.J., 2000. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213.
122. Labutta, J.L., Miles, R.B., Sanes, J.N., Hallet, M., 1994. Motor program memory storage in Parkinson's disease patients tested with a delayed response task. Movement Disorders: Official Journal of the Movement Disorder Society 9, 218-222.
123. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I., 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
124. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D., 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology 46, 598-605.
125. Langston, J.W., Quick, M., Petzinger, G., Jakowec, M., Di Monte, D.A., 2000. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Annals of Neurology 47, S79-S89.
126. Lee, C.S., Sauer, H., Björklund, A., 1996. Dopaminergic neuronal degeneration and motor impairments following lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72, 641-653.
127. Lee, H.J., Youn, J.M., Mary J.O., Gallagher, M., Holland, P.C., 2006. Role of substantia nigra-amygdala connections in surprise-induced enhancement of attention. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 26, 6077-6081.
128. Lee, H.J., Smith, E.S., Geissler, S.A., Schallert, T., 2011. Unilateral central amygdala dopamine depletion impairs capacity to disengage from ongoing behavior in response to contralateral somtatosensory stimulation. In: Proceedings of the 41st Annual Meeting of the Society for Neuroscience (SfN), p. #294.15.
129. Li, F.Q., Wang, T., Pei, Z., Liu, B., Hong, J.S., 2005. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. Journal of Neural Transmission 112, 331-347.
130. Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S., Collins, F., 1993. GDNF: a glial cell linederived neurotrophic factor for midbrain dopaminergic neurons. Science 21, 1130-1132.
131. Linder, J.C., Young, S.J., Groves, P.M., 1995. Electron microscopic evidence for neurotoxicity in the basal ganglia. Neurochemistry International 26, 195-202.
132. Lindner, M.D., Winn, S.R., Baetge, E.E., Hammang, J.P., Gentile, F.T., Doherty, E., et al., 1995. Implantation of encapsulated catecholamine and GDNF producing cells in rats with unilateral dopamine depletions and Parkinsonian symptoms. Experimental Neurology 132, 62-76.
133. Lindner, M.D., Plone, M.A., Francis, J.M., Blaney, T.J., Salamone, J.D., Emerich, D.F., 1997. Rats with partial striatal dopamine depletions exhibit robust and longlasting behavioral deficits in a simple fixedratio bar-pressing task. Behavioural Brain Research 86, 25-40.
134. Litvan, I., Aarsland, D., Adler, C.H., Goldman, J.G., Kulisevsky, J., Mollenhauer, B., et al., 2011. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Movement Disorders: Official Journal of the Movement Disorder Society 26, 1814-1824.
135. Luchtman, D.W., Meng, Q., Song, C., 2012. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behavioural Bran Research 226, 386-396.
136. Lundblad, M., Picconi, B., Lindgren, H., Cenci, M.A., 2004. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease 16, 110-123.
137. Lynch, C.B., 1980. Response to divergent selection for nesting behavior in Mus musculus. Genetics 96, 757-765.
138. Maggio, R., Babier, P., Corsini, G.U., 1995. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Journal of Neural Transmission. Supplementum 45, 133-136.
139. Mandel, R., Brundin, P., Björklund, A., 1990. The importance of graft replacement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. The European Journal of Neuroscience 2, 888-894.
140. Marien, M.R., Colpaert, F.C., Rosenquist, A.C., 2004. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Research. Brain Research Reviews 45, 38-78.
141. Marshall, J.F., Levitan, D., Stricker, E.M., 1976. Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. Journal of Comparative and Physiological Psychology 90, 536-546.
142. Mayeux, R., Marder, K., Cote, L.J., Denaro, J., Hemenegildo, N., Mejia, H., et al., 1995. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. American Journal of Epidemiology 142, 820-827.
143. Meaney, M.J., Brake, W., Gratton, A., 2001. Environmental regulation of mesolimbic dopamine systems: a neurobiological mechanism for vulnerability to drug abuse? Psychoneuroendocrinology 27, 127-138.
144. Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., Cenci, M.A., 2007. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Journal of Neurochemistry 101, 483-497.
145. Mendez, J.S., Finn, B.W., 1975. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Annals of Neurology 42, 166-173.
146. Miklyaeva, E.I., Castañeda, E., Whishaw, I.Q., 1994a. Skilled reaching deficits in unilateral dopamine-depleted rats: impairments in movement and posture and compensatory adjustments. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14, 7148-7158.
147. Miklyaeva, E.I., Castaneda, E., Whishaw, I.Q., 1994b. Skilled reaching deficits in unilateral dopamine-depleted rats: impairments in movement and posture and compensatory adjustments. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14, 7148-7158.
148. Millan, M.J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.A., Newman-Tancredi, A., 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics 303, 791-804.
149. Miyoshi, E., Wietzikosi, S., Camplessei, M., Silveira, R., Takahashi, R.N., Da Cunha, C., 2002. Impaired learning in a spatial working memory version ad in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Research Bulletin 58, 41-47.
150. Montoya, C.P., Astell, S., Dunnett, S.B., 1990. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Progress in Brain Research 82, 459-466.
151. Montoya, C.P., Campbell-Hope, L.J., Pemberton, K.D., Dunnett, S.B., 1991. The staircase test: a measure of independent forelimb reaching and grasping abilities in rats. Journal of Neuroscience Methods 36, 219-228.
152. Moreira, C.G., Barbiero, J.K., Ariza, D., Dombrowski, P.A., Sabioni, P., Bortolanza, M., et al., 2012. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin. Neurotoxicity Research 21, 291-301.
153. Morris, R.G.M., 1982. An attempt to dissociate spatial-mapping and working- memory theories of hippocampal function. In: Siefert, W. (Ed.), Molecular, Cellular and Behavioural Neurobiology of the Hippocampus. Academic Press, New York.
154. Morris, R.G.M., Garrud, P., Rawlins, J.N.P., O'Keefe, J., 1982. Place navigation impaired in rats with hippocampal lesions. Nature 297, 681-683.
155. Morris, R.G.M., 1984. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 11, 47-60.
156. Mu, X., He, G.R., Yuan, X., Li, X.X., Du, G.H., 2011. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. Pharmacology, Biochemistry, and Behavior 98, 286-291.
157. Mukhida, K., Baker, K.A., Sadi, D., Mendez, I., 2001. Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21, 3521-3530.
158. Nikkhah, G., Duan, W.M., Knappe, U., Jödicke, A., Björklund, A., 1993. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 56, 33-43.
159. Nikkhah, G., Olsson, M., Eberhard, J., Bentlage, C., Cunningham, M.G., Björklund, A., 1994a. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63, 57-72.
160. Nikkhah, G., Bentlage, C., Cunningham, M.G., Björklund, A., 1994b. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14, 3449-3461.
161. Ogawa, N., Hirose, Y., Ohara, S., Ono, T., Watanabe, Y., 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Research Communications in Chemical Pathology and Pharmacology 50, 435-441.
162. Olanow, C.W., Tatton, W.G., 1999. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 22, 123-144.
163. Olsson, M., Nikkhah, G., Bentlage, C., Björklund, A., 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 15, 3863-3875.
164. Owen, A.M., Roberts, A.C., Polkey, C.E., Sahakian, B.J., Robbins, T.W., 1991. Extradimensional versus intra-dimensional set shofting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychology 29, 993-1006.
165. Packard, M.G., McGaugh, J.L., 1992. Double dissociation of fornix and caudate nucleus lesions on acquisition of two water maze tasks: further evidence for multiple memory systems. Behavioral Neuroscience 106, 439-446.
166. Pakkenberg, B., Moller, A., Gundersen, H.J.G., Mouritzen-Dam, A., Pakkenberg, H., 1991. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. Journal of Neurology, Neurosurgery, and Psychiatry 54, 30-33.
167. Pardon, M.-C., Rattray, I., 2008. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neuroscience and Biobehavioral Reviews 32, 1103-1120.
168. Parker Jr., W.D., Boyson, S.J., Parks, J.K., 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Annals of Neurology 26, 719-723.
169. Pascual Leone, A., Hallett, M., 1994. Induction iof errors in a delayed response task by repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex. Neuroreport 5, 2517-2520.
170. Pereira, E.A., Nandi, D., Jenkinson, N., Stein, J.F., Green, A.L., Aziz, T.Z., 2011. Pedunculopontine stimulation from primate to patient. Journal of Neural Transmission 118, 1453-1460.
171. Petroske, E., Meredith, G.E., Callen, S., Totterdell, S., Lau, Y.S., 2001. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106, 589-601.
172. Pienaar, I.S., Kellaway, L.A., Russell, V.A., Smith, A.D., Stein, D.J., Zigmond, D.J., Daniels, W.M., 2008. Maternal separation exaggerates the toxic effects of 6-hydroxydopamine in rats: implications for neurodegenerative disorders. Stress 11, 448-456.
173. Pifl, C., Schingnitz, G., Hornykiewicz, O., 1991. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605.
174. Playford, E.D., Jenkins, I.H., Passingham, R.E., Nutt, J., Frackowiak, R.S., Brooks, D.J., 1992. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Annals of Neurology 32, 151-161.
175. Pollard, H.B., Dhariwal, K., Adeyemo, O.M., Markey, C.J., Caohuy, H., Levine, M., Markey, S., Youdim, M.B., 1992. A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 6, 3108-3116.
176. Prediger, R.D.S., Pamplona, F.A., Fernandes, D., Takahashi, R.N., 2005. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)-the spontaneously hypertensive rat (SHR). The International Journal of Neuropsychopharmacology 8, 583-594.
177. Prediger, R.D.S., Batista, L.C., Medeiros, R., Pandolfo, P., Florio, J.C., Takahashi, R.N., 2006. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental Neurology 202, 391-403.
178. Protas, E.J., Mitchell, K., Williams, A., Qureshy, H., Caroline, K., Lai, E.C., 2005. Gait and step training to reduce falls in Parkinson's disease. Neurorehabilation 20, 183-190.
179. Przedborski, S., Levivier, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., Togasaki, D.M., 1995. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631-647.
180. Przedborski, S., Jackson-Lewis, V., Naini, A.B., Jakowec, M., Petzinger, G., Miller, R., Akram, M., 2001. The parkinsonian toxin 1-methul-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. Journal of Neurochemistry 76, 1265-1274.
181. Raskin, S.A., Borod, J.C., Tweedy, J.R., 1992. Set-shifting and spatial orientation in patients with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society 14, 801-821.
182. Rascol, O., Clanet, M., Motastruc, J.L., Simonetta, M., Soulier-Esteve, M.J., Doyon, B., Rascol, A., 1989. Abnormal ocular movements in Parkinson's disease. Brain 112, 1193-1214.
183. Ricaurte, G.A., Irwin, I., Forno, L.S., DeLanney, L.E., Langston, E., Langston, J.W., 1987. Aging and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Research 403, 43-51.
184. Richards, M., Stern, Y., Marder, K., Cote, L., Mayeux, R., 1993. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal elderly individuals. Annals of Neurology 33, 267-274.
185. Riederer, P., Wuketich, S., 1976. Time course of nigrostriatal degeneration in Parkinson's disease. Journal of Neural Transmission 38, 277-301.
186. Rieger, B., Markowitsch, H.J., 1996. Implicit and explicit mnestic performance of patients with prefrontal, medial temporal, and basal ganglia damage. Neurology, Psychiatry and Brain Research 4, 53-74.
187. Robinson, T.E., Noordhoorn, M., Chan, E.M., Mocsary, Z., Camp, D.M., Whishaw, I.G., 1994. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra. Synapse 17, 16-25.
188. Roedter, A., Winkler, C., Samii, M., Walter, G.F., Brandis, A., Nikkhah, G., 2001. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways. The Journal of Comparative Neurology 432, 217-229.
189. Rommelfanger, K.S., Weinshenker, D., 2007. Norepinephrine: the red-headed stepchild of Parkinson's disease. Biochemical Pharmacology 74, 177-190.
190. Rozas, G., Guerra, M.J., Labandeira-Garcia, J.L., 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Research Protocols 2, 75-84.
191. Rozas, G., Labandeira Garcia, J.L., 1997. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Research 749, 188-199.
192. Sacrey, L.A., Alaverdashvili, M., Whishaw, I.Q., 2009a. Similar hand shaping in reaching-for-food (skilled reaching) in rats and humans provides evidence of homology in release, collection, and manipulation movements. Behavioural Brain Research 204, 153-161.
193. Sacrey, L.A., Clark, C.A., Whishaw, I.Q., 2009b. Music attenuates excessive visual guidance of skilled reaching in advanced but not mild Parkinson's disease. PLoS One 4, e6841.
194. Sacrey, L.A., Whishaw, I.Q., 2010. Development of collection precedes targeted reaching: resting shapes of the hands and digits in 1-6-month-old human infants. Behavioural Brain Research 214, 125-129.
195. Sacrey, L.A., Travis, S.G., Whishaw, I.Q., 2011. Drug treatment and familiar music aids an attention shift from vision to somatosensation in Parkinson's disease on the reach-to-eat task. Behavioural Brain Research 217, 391-398.
196. Saint-Cyr, J.A., Taylor, A.E., Nicholson, K., 1995. Behavior and the basal ganglia. In: Weiner, W.J., Lang, A.E. (Eds.), Behavior Neurology of Movement Disorders. Raven Press, New York, pp. 1-28.
197. Sakai, K., Gash, D.M., 1994. Effect of bilateral 6-OHDA lesions of the substantia Nigra on locomotor activity in the rat. Brain Research 633, 144-150.
198. Samoudi, G., Nissbrandt, H., Dutia, M.B., Bergquist, F., 2012. Noisy galvanic vestibular stimulation promotes GABA release in the substantia nigra and improves locomotion in hemiparkinsonian rats. PLoS One 7, e29308.
199. Sanchez, M.M., Ladd, C.O., Plotsky, P.M., 2001. Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Development and Psychopathology 13, 419-449.
200. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J.A., Herve, D., Greengard, P., Fisone, G., 2007. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 27, 6995-7005.
201. Sapolsky, R.M., 1992. Stress, the Aging Brain, and the Mechanisms of Neuron Death. MIT Press, Cambridge MA.
202. Sasco, A.J., Paffenbarger Jr., R.S., Gendre, I., Wing, A.L. 1992. The role of physical exercise in the occurrence of Parkinson's disease. Archives of Neurology 49, 360-365.
203. Sauer, H., Oertel, W.H., 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde and immunocytochemical study in the rat. Neuroscience 59, 401-415.
204. Sawaguchi, T., Goldman-Rakic, P.S., 1991. D1 dopamine receptors in prefrontal cortex: involvemnet in working memory. Science 251, 947-950.
205. Schallert, T., De Ryck, M., Whishaw, I.Q., Teitelbaum, P., 1979. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Journal of Experimental Neurology 64, 33-43.
206. Schallert, T., Hall, S., 1988. 'Disengage' sensorimotor deficit following apparent recovery from unilateral dopamine depletion. Behavioural Brain Research 30, 15-24.
207. Schallert, T., 1989. Preoperative intermittent feeding or drinking regimens enhance post-lesion sensorimotor function. In: Schulkin, J. (Ed.), Preoperative Events: Their Effects on Behavior following Brain Damage. Lawrence Erlbaum Association, New Jersey, pp. 1-20.
208. Schallert, T., Norton, D., Jones, T.A., 1992. A clinically relevant unilateral rat model of parkinsonian akinesia. Journal of Neural Transplantation and Plasticity 3, 332-333.
209. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L., Bland, S.T., 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777-787.
210. Schmidt, N., Ferger, B., 2001. Neurochemical findings in the MPTP model of Parkinson's disease. Journal of Neural Transmission 108, 1263-1282.
211. Schmidt, W.J., Alam, M., 2006. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease PD. Journal of Neural Transmission 70, 273-276.
212. Schneider, J.S., Markham, C.H., 1986. Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine MPTP in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Research 373, 258-267.
213. Schneider, J.S., Kovelowski, C.J., 1990. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Research 519, 122-128.
214. Schober, A., 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell and Tissue Research 318, 215-224.
215. Schwab, R.S., Zieper, I., 1965. Effects of mood, motivation, stress, and alertness on the performance in Parkinson's disease. Psychiatria et Neurologia 150, 345-357.
216. Schwarting, R.K., Bonatz, A.E., Carey, R.J., Huston, J.P., 1991. Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxydopamine injections. Brain Research 554, 46-55.
217. Sedelis, M., Hofele, K., Auburger, G.W., Morgan, S., Huston, J.P., Schwarting, R.K., 2000. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behavior Genetics 30, 171-182.
218. Selkoe, D.J., 1994. Alzheimer's disease: a central role for amyloid. Journal of Neuropathology and Experimental Neurology 53, 438-447.
219. Shan, L., Bossers, K., Luchetti, S., Balesar, R., Lethbridge, N., Chazot, P.L., et al., 2012. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a post-mortem study. Neurobiology of Aging 33, 1488.e1-1488.e13.
220. Sherer, T.B., Kim, J.-H., Betarbet, R., Greenamyre, T., 2003. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Experimental Neurology 179, 9-16.
221. Shi, L.-H., Woodward, D.J., Luo, F., Anstrom, K., Schallert, T., Chang, J.Y., 2004. High frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions. Brain Research 1013, 98-106.
222. Shoffner, J.M., Watts, R.L., Juncos, J.L., Torroni, A., Wallace, D.C., 1991. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Annals of Neurology 30, 332-339.
223. Simola, N., Morelli, M., Carta, A.R., 2007. The 6-hydroxydopamine model of Parkinson's disease. Neurotoxicity Research 11, 151-187.
224. Sindhu, K.M., Banarjee, R., Senthilkumar, K.S., Saravanan, K.S., Raju, B.C., Rao, J.M., Mohanakumar, K.M., 2006. Rats with unilateral median forebrain bundle, but not striatal or nigral lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacology, Biochemistry, and Behavior 84, 321-329.
225. Singer, G., Armstrong, S., 1976. Effects of intracranial injections of 6-OHDA on food and water intakes, body temperature and body weight regulation in the rat. Pharmacology, Biochemistry, and Behavior 5, 309-317.
226. Silverdale, M.A., Kobylecki, C., Hallett, P.J., Li, Q., Dunah, A.W., Ravenscroft, P., Bezard, E., Brotchie, J.M., 2010. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 64, 177-180.
227. Slovin, H., Abeles, M., Vaadia, E., Haalman, I., Prut, Y., Bergman, H., 1999. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys. Journal of Neurophysiology 81, 858-874.
228. Smeyne, R.J., Jackson-Lewis, V., 2005. The MPTP model of Parkinson's disease. Brain Research. Molecular Brain Research 134, 57-66.
229. Smith, A.D., Castro, S.L., Zigmond, M.J., 2002. Stress-induced Parkinson's disease: a working hypothesis. Physiology & Behavior 77, 527-531.
230. Sofic, E., Sapcanin, A., Tahirovic, I., Gavrankapetanovic, I., Jellinger, K., Reynolds, G.P., Tatschner, T., Riederer, P., 2006. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. Journal of Neural Transmission. Supplementum 71, 39-43.
231. Souques, A.A., 1921. Kinesie paradoxicale. Revista de Neurologia 37, 559-560.
232. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., 1997. Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
233. Stern, Y., Langston, J.W., 1985. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology 35, 1506-1509.
234. Stern, Y., Tetrud, J.W., Martin, W.R.W., Kutner, S.J., Langston, J.W., 1990. Cognitive changes following MPTP exposure. Neurology 40, 261-264.
235. Stern, Y., Richards, M., Sano, M., Mayeux, R., 1993. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Archives of Neurology 50, 1040-1045.
236. Sulzer, D., Chen, T.K., Lau, Y.Y., Kristensen, H., Rayport, S., Ewing, A., 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 15, 4102-4108.
237. Sundström, E., Samuelsson, E.B., 1997. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Pharmacology & Toxicology 81, 226-231.
238. Szczypka, M.S., Kwok, K., Brot, M.D., Marck, B.T., Matsumoto, A.M., Donahue, B.A., Palmiter, R.D., 2001. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30, 819-828.
239. Tadaiesky, M.T., Dombrowski, P.A., Figueiredo, C.P., Cargnin-Ferreira, E., Da Cunha, C., Takahashi, R.N., 2008. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156, 830-840.
240. Tajiri, N., Yasuhara, T., Shingo, T., Kondo, A., Yuan, W., Kadota, T., Wang, F., Baba, T., et al., 2010. Exercise exerts neuroprotective effects on Parkinson's disease model of rats. Brain Research 1310, 200-207.
241. Tanner, C.M., Kamel, F., Ross, G.W., Hoppin, J.A., Goldman, S.M., Korell, M., Marras, C., Bhudhikanok, G.S., et al., 2011. Rotenone, Paraquat and Parkinson's disease. Environmental Health Perspectives 119, 866-872.
242. Tarsy, D., 2012. Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. JAMA: the Journal of the American Medical Association 307, 2305-2314.
243. Taylor, A.E., Saint-Cyr, J.A., Lang, A.E., 1986. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain 109, 845-883.
244. Testa, C.M., Sherer, T.B., Greenamyre, J.T., 2005. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Bran Research. Molecular Brain Research 134, 109-118.
245. Tillerson, J.L., Cohen, A.D., Philhower, J., Miller, G.W., Zigmond, M.J., Schallert, T., 2001. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21, 4427-4435.
246. Tillerson, J.L., Caudle, W.M., Reverón, M.E., Miller, G.W., 2002. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Experimental Neurology 178, 80-90.
247. Tillerson, J.L., Miller, G.W., 2003. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. Journal of Neuroscience Methods 123, 189-200.
248. Tipton, K.F., Singer, T.P., 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of Neurochemistry 61, 1191-1206.
249. Torres, E.M., Dowd, E., Dunnett, S.B., 2008. Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience 154, 631-640.
250. Truong, L., Allbutt, H., Kassiou, M., Henderson, J.M., 2006. Developing a preclinical model of parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behavioural Brain Research 169, 1-9.
251. Tsai, C.H., Lo, S.K., See, L.C., Chen, H.Z., Chen, R.S., Weng, Y.H., Chang, F.C., Lu, C.S., 2002. Environmental risk factors of young onset Parkinson's disease: a case-control study. Clinical Neurology and Neurosurgery 104, 328-333.
252. Tseng, K.Y., Kargieman, L., Gacio, S., Riquelme, L.A., Murer, M.G., 2005. Consequences of partial and severe dopaminergic lesion on basal ganglia oscillatory activity and akinesia. The European Journal of Neuroscience 22, 2579-2586.
253. Uchida, K., Tsuzaki, N., Nagatsu, T., Kohsaka, S., 1992. Tetrahydrobiopterindependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblast transfected with tyrosine hydroxylase cDNA. Developmental Neuroscience 14, 173-180.
254. Ungerstedt, U., Arbuthnott, G.W., 1970. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Research 24, 485-493.
255. Ungerstedt, U., 1971a. Stereotaxic mapping of the of the monoamine pathway in the rat brain. Acta Physiologica Scandinavica 367, 1-48.
256. Ungerstedt, U., 1971b. Adipsia and aphagia after 6-hydroxydopamine induced degeneration system. Acta Physiologica Scandinavica. Supplementum 367, 95-122.
257. Ungerstedt, U., Pycock, C., 1974. Functional correlates of dopamine neurotransmission. Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften 1278, 1-5.
258. Ungerstedt, U., 1976. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacology & Toxicology 2, 37-40.
259. Ungerstedt, U., Herrera-Marschitz, M., Jungnelius, U., Ståhle, L., Tossman, U., Zetterstrom, T., 1982. Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis. Advances in the Biosciences 37, 219-231.
260. Upchurch, M., Schallert, T., 1983. A behavior analysis of the offspring of haloperidolsensitive and haloperidol-resistant gerbils. Behavioral and Neural Biology 39, 221-228.
261. Vergara-Aragon, P., Gonzalez, C.L., Whishaw, I.Q., 2003. A novel skilled-reaching impairment in paw supination on the good side of the hemi-Parkinson rat improved with rehabilitation. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23, 579-586.
262. Villani, L., Beraudi, A., Giuliani, A., Poli, A., 2001. MPTP-induced apoptosis in the retina of goldfish. Neurotoxicity Research 3, 255-257.
263. Whishaw, I.Q., O'Connor, W.T., Dunnett, S.B., 1986. The contributions of motor cortex, nigrostriatal dopamine and caudate-putamen to skilled forelimb use in the rat. Brain 109 (Pr 5), 805-843.
264. Whishaw, I.Q., Pellis, S.M., 1990. The structure of skilled forelimb reaching in the rat: a proximally driven movement with a single distal rotatory component. Behavioural Brain Research 41, 49-59.
265. Whishaw, I.Q., Gorny, B., Tran-Nguyen, L.T., Castaneda, E., Miklyaeva, E.I., Pellis, S.M., 1994. Making two movements at once: impairments of movement, posture, and their integration underlie the adult skilled reaching deficit of neonatally dopamine-depleted rats. Behavioural Brain Research 61, 65-77.
266. Whishaw, I.Q., Suchowersky, O., Davis, L., Sarna, J., Metz, G.A., Pellis, S.M., 2002. Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models. Behavioural Brain Research 133, 165-176.
267. Woodlee, M.T., Asseo-Garcia, A.M., Zhao, X., Liu, S.J., Jones, T.A., Schallert, T., 2005. Testing forelimb placing across the midline reveals distinct, lesion-dependent patterns of recovery in rats. Experimental Neurology 191, 310-317.
268. Woodlee, M., Kane, J.R., Chang, J., Cormack, L.K., Schallert, T., 2008. Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability? Experimental Neurology 211, 511-517.
269. Wu, J.A., Attele, A.S., Zhang, L., Yuan, C.S., 2001. Anti-HIV activity of medicinal herbs: usage and potential development. The American Journal of Chinese Medicine 29, 69-81.
270. Yenice, O., Onal, S., Midi, I., Ozcan, E., Temel, A., I-Gunal, D., 2008. Visual field analysis in patients with Parkinson's disease. Parkinsonism & Related Disorders 14, 193-198.
271. Young, D., Lawlor, P.A., Leone, P., Dragunow, M., During, M.J., 1999. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nature Medicine 5, 448-453.
272. Zetterström, T., Herrera-Marschitz, M., Ungerstedt, U., 1986. Simultaneous measurement of dopamine release and rotational behavior in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Research 376, 1-7.
273. Zigmond, M.J., Stricker, E.M., 1973. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182, 717-720.
274. Zimmerman, M., Chelminski, I., McDermut, W., 2002. Major depressive disorder and axis I diagnostic comorbidity. Journal of Clinical Psychology 63, 187-193.